Qyuns Hands Caldera Preclinical TL1A×IL-17 BsAb for Up to USD 780mn

Qyuns Therapeutics has granted Caldera Therapeutics worldwide rights to a preclinical TL1A×IL-17 bispecific antibody (BsAb), receiving a USD 30 million non-refundable upfront payment and eligibility for up to USD 750 million in clinical, regulatory and commercial milestones, plus tiered royalties on net sales.

The deal gives Caldera full global control of research, development, manufacturing and commercialisation while allowing Qyuns to monetise an early-stage immunology asset without carrying the full development burden.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details